Background Enhancing quality of life (QoL) is the primary aim of palliative care and a key endpoint in oncology research. Objective This study aimed to assess the QoL and its association with anxiety, depression, and clinical factors among patients with metastatic cancer attending oncology centers in Northwest Ethiopia. Design A cross-sectional study was conducted among 290 cancer patients with metastasis who were receiving treatment at oncologic centers in Northwest Ethiopia from August to October 2023. Methods Study participants were enrolled using the consecutive sampling method. QoL was measured using the World Health Organization Quality of Life Scale – Brief Version (WHOQOL-BREF). Multiple linear regression analysis was used to identify the determinants of QoL. Variables with a P-value < 0.05 at a 95% confidence interval were considered statistically significant. Results In this study, the mean scores for physical health, psychological health, social relationships, environmental health, and overall QoL were 26.74±10.09, 30.46±12.03, 34.48±13.97, 37.64±14.06, and 31.17±6.51, respectively. The overall QoL had a negative significant association with poor performance status (β = -2.52; 95% CI: -4.35, -0.69), presence of comorbidity (β = -2.46; 95% CI: -4.03, -0.90), depression (β = -3.17; 95% CI: -4.76, -1.59), anxiety (β = -1.99; 95% CI: -3.38, -0.47), and poor social support (β = -2.52; 95% CI: -4.43, -0.61). Conclusion The physical health domain of QoL had the lowest mean score. Poor performance status, the presence of comorbidity, depression, anxiety, and poor social support were the determinants of overall QoL. Hence, it is essential to focus on treatments that enhance physical health, improve poor performance status, manage comorbidities, alleviate depression and anxiety, and strengthen social support.
Fasil Bayafers Tamene, Tirsit Kestela Zeleke, Endalamaw Aschale Mihiretie et al.· Palliative Care and Social P...· 0 citations
Type 2 diabetes mellitus (T2DM) is a metabolic disease that requires continuous medical care. Attaining glycemic control in patients with T2DM usually requires more complicated medication regimens. Increased medication regimen complexity (MRC) may affect glycemic control. This study aimed to assess the complexity of medication regimens and its association with glycemic control among patients with T2DM at the Debre Birhan Comprehensive and Specialized Hospital (DBCSH). A hospital-based cross-sectional study was conducted at DBCSH from April 30 to July 30, 2025. Medication Regimen Complexity Index (MRCI), a 65-item validated tool, was used to assess MRC. MRCI scores were calculated using Microsoft Access Version 1.0. Glycemic control was assessed using fasting blood glucose (FBG), as HbA1c measurement was not available in the study setting. The data were analyzed using SPSS version 27. A p-value of less than 0.05 at a 95% confidence interval was considered a significant variable in multivariable analysis. A total of 370 patients with T2DM were included in the final analysis. More than half of the patients were female (56.5%). About 30% of the participants were classified as having a high diabetes-specific MRCI, whereas 27.3% of the participants were classified as having high patient-specific MRCI. Compared with low MRCI, moderate diabetes-specific MRCI (AOR = 2.2; 95% CI = 1.1–4.1), moderate patient-specific MRCI (AOR = 3.4; 95% CI = 1.5–5.3), and high patient-specific MRCI (AOR = 6.6; 95% CI = 2.8–15.6) were significantly associated with poor glycemic control. The findings of this study showed that patients with T2DM have high medication regimen complexity. It also revealed that moderate diabetes-specific MRC and moderate and high patient-specific MRC were significantly associated with poor glycemic control. Further prospective cohort studies are needed to determine the temporal relationship between medication regimen complexity and glycemic control.
Emneteab Mesfin Ayele, M. Seid, Samuel Agegnew Wondm· Scientific Reports· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
